Low-Level Viremia and Proviral DNA Impede Immune Reconstitution in HIV-1--Infected Patients Receiving Highly Active Antiretroviral Therapy

Ostrowski, Sisse R.; Katzenstein, Terese L.; Thim, Per T.; Pedersen, Bente K.; Gerstoft, Jan; Ullum, Henrik
February 2005
Journal of Infectious Diseases;2/1/2005, Vol. 191 Issue 3, p348
Academic Journal
Background. Immunological and virological consequences of low-level viremia in human immunodeficiency virus (HIV) type 1-infected patients receiving highly active antiretroviral therapy (HAART) remain to be determined. Methods. For 24 months, 101 HAART-treated, HIV-1-infected patients with HIV RNA levels ⩽200 copies/mL were followed prospectively: HIV RNA level and CD4 and CD8 cell counts were investigated every 3 months, and proviral DNA and T cell subsets were investigated every 6 months. Results. During follow-up, 33 patients had HIV RNA levels ⩽20 copies/mL at all visits (uVL patients), where-as 68 patients had HIV RNA levels >20 copies/mL at ⩾1 visit (dVL patients) (median increase, 81 copies/mL [interquartile range, 37-480 copies/mL]). dVL patients had higher concentrations of CD8 cells, activated and memory T cells, and proviral DNA, compared with uVL patients (P<.05). A higher HIV RNA level was independently associated with reduced CD4 gain (P<.001). A higher HIV RNA level also was associated with increases in activated CD8+CD38+ and CD8+HLA-DR+ cells (P< .05), and a higher level of activated CD8+CD38+ cells was independently associated with reduced CD4 gain (P < .05). A higher proviral DNA level was associated with increases in CD4+CD45RA-D28- effector cells and reductions in naive CD4+CD45RA+CD62L+ and CD8+CD45RA+CD62L+ cells (P<.05). Higher levels of activated CD4+HLA-DR+ and early differentiated CD4+CD45RA-D28+ cells predicted increased risk of subsequent detectable viremia in patients with undetectable HIV RNA (P<.05). Conclusion. These findings indicate that low-level viremia and proviral DNA are intimately associated with the immunological and virological equilibrium in patients receiving HAART.


Related Articles

  • Early Treatment and HIV-1 Reservoirs: A Stitch in Time? Henrich, Timothy J.; Gandhi, Rajesh T. // Journal of Infectious Diseases;Oct2013, Vol. 208 Issue 8, p1189 

    The article presents the author's comments on the implications of antiretroviral therapy (ART) during acute human immunodeficiency virus type 1 (HIV-1) infection on viral reservoirs. It specifically refers to a study which examined HIV-1 nucleic acid levels and T-cell activation in patients who...

  • HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Manfredi, Roberto; Sabbatani, Sergio; Fasulo, Giovanni // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p501 

    An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described. An international literature search allowed...

  • South Africans Win Some, Lose Some. Houlton, Sarah // Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p24 

    Reports that the South African government has approved the provision of antiretroviral drugs to HIV-positive South Africans. Funding by the Global Fund to Fight AIDS, Malaria and Tuberculosis of an AIDS program in KwaZulu Natal.

  • Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Therapy Containing Once-Daily Abacavir, Lamivudine, and Tenofovir DF in Treatment-Naive HIV-Infected Patients. Khanlou, Homayoun; Yeh, Vivian; Guyer, Bill; Farthing, Charles // AIDS Patient Care & STDs;Mar2005, Vol. 19 Issue 3, p135 

    Previous investigational data using abacavir (ABC), lamuvidine (3TC), and zidovudine has suggested the possibility of triple nucleoside analogue reverse transcriptase inhibitors (NRTI) therapy as an option in the treatment of HIV infection. We performed a pilot study to assess the potency of...

  • Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection. Gentz, Mark; Levin, Todd P.; Klibanov, Olga M.; Feingold, Anat; Condoluci, David V. // AIDS Patient Care & STDs;Nov2006, Vol. 20 Issue 11, p741 

    Antiretroviral resistance in treatment-naïve patients with HIV-1 infection is on the rise in both resource-rich and resource-poor countries. We report a case of three-class primary antiretroviral resistance detected by a genotypic assay in a 19-year-old woman with acute HIV-1 infection. Her...

  • Human Immunodeficiency Virus (HIV) and endodontics: a review. Bürklein, Sebastian; Schäfer, Edgar // Endodontic Practice Today;2007, Vol. 1 Issue 1, p37 

    Due to the introduction of highly active antiretroviral therapy (HAART), HIV infection has gradually become more of a chronic immunodeficiency disease. In response to HAART, the CD4 cell count, in most cases, increases and thereby the HIV-infected patients are at a lower risk of developing...

  • Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients. Pol, Stanislas; Soriano, Vincent // Clinical Infectious Diseases;7/1/2008, Vol. 47 Issue 1, p94 

    The managment of chronic hepatitis C virus infection in patients coinfected with the human immunodeficiency virus poses a significant challenge. Treatment is influenced by a number of viral and host characteristics, including hepatitis C virus genotype, baseline viremia, and adherence to...

  • Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients. Espíndola, Milena S.; Lima, Leonardo J. G.; Soares, Luana S.; Cacemiro, Maira C.; Zambuzi, Fabiana A.; de Souza Gomes, Matheus; Amaral, Laurence R.; Bollela, Valdes R.; Martins-Filho, Olindo A.; Frantz, Fabiani G. // PLoS ONE;12/18/2015, Vol. 10 Issue 12, p1 

    Background: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological...

  • Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients. Moore, Richard D.; Bartlett, John G.; Gallant, Joel E. // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Introduction: HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics